These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 24890683)

  • 1. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
    Leiter LA; Cefalu WT; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    J Am Geriatr Soc; 2014 Jul; 62(7):1252-62. PubMed ID: 24890683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
    Cefalu WT; Leiter LA; de Bruin TW; Gause-Nilsson I; Sugg J; Parikh SJ
    Diabetes Care; 2015 Jul; 38(7):1218-27. PubMed ID: 25852208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
    Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
    Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
    J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
    Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
    Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
    Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
    J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
    Parikh S; Wilding J; Jabbour S; Hardy E
    Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
    Weber MA; Mansfield TA; Alessi F; Iqbal N; Parikh S; Ptaszynska A
    Blood Press; 2016; 25(2):93-103. PubMed ID: 26623980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
    Nauck MA; Del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Diabetes Care; 2011 Sep; 34(9):2015-22. PubMed ID: 21816980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
    Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
    Yang W; Han P; Min KW; Wang B; Mansfield T; T'Joen C; Iqbal N; Johnsson E; Ptaszynska A
    J Diabetes; 2016 Nov; 8(6):796-808. PubMed ID: 26589253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.
    Ljunggren Ö; Bolinder J; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2012 Nov; 14(11):990-9. PubMed ID: 22651373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
    Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
    Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.